急诊科大麻中毒的主诉、药物检测与神经影像学检查
这项回顾性研究利用Epic Cosmos数据库(2016年1月至2024年6月),纳入3653例<6岁儿童大麻中毒急诊就诊,评估主诉与神经影像学使用的关系及药物检测结果回报时间。最常见主诉为精神状态改变(39%),其次为摄入/暴露(35%),癫痫/异常运动占5%。从到院至大麻检测采集和结果回报的中位时间分别为93分钟和152分钟。神经影像学检查使用率为35%,摄入主诉者显著低于神经系统主诉者(8.8% vs 56%;OR 0.08,95% CI:0.06-0.10)。作者认为这些发现强调需要促进照护者早期披露摄入并加快药物筛查以优化诊疗。
要点
- 儿童大麻中毒急诊就诊中神经影像学检查使用率为35%,摄入/暴露主诉者显著低于神经系统主诉者(8.8% vs 56%;OR 0.08,95% CI:0.06-0.10)。
- 从急诊到院至大麻检测采集的中位时间为93分钟(IQR 40-208),至结果回报的中位时间为152分钟(IQR 90-277),药物筛查结果常迟至就诊后期才可获得。
- 最常见主诉为精神状态改变(39%),其次为摄入/暴露(35%),癫痫/异常运动占5%。
- 作者认为需要促进照护者早期披露摄入并加快药物筛查的策略,以优化儿童大麻中毒的急诊诊疗。
适用人群与场景
- 纳入标准:<6岁儿童,急诊就诊,诊断为大麻中毒且行大麻实验室检测;数据来源于Epic Cosmos数据库,时间范围为2016年1月至2024年6月。
研究设计与关键结果
- 研究类型:回顾性研究,使用Epic Cosmos数据库(2016年1月-2024年6月),纳入3653例<6岁儿童大麻中毒急诊就诊。
- 人群特征:中位年龄29个月(IQR 16-45),女性占51%,白人占41%,黑人占35%,西班牙裔占15%。
- 主诉分布:精神状态改变最常见(39%),其次为摄入/暴露(35%),癫痫/异常运动占5%。
- 时间指标:从急诊到院至大麻检测采集的中位时间为93分钟(IQR 40-208),至结果回报的中位时间为152分钟(IQR 90-277)。
- 神经影像学检查使用率为35%;摄入/暴露主诉者使用率8.8%,显著低于神经系统主诉者的56%(OR 0.08,95% CI:0.06-0.10)。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于儿童大麻中毒,药物筛查结果常迟至急诊就诊后期才可获得,且主诉强烈影响神经影像学的使用;这些发现强调需要促进照护者早期披露摄入并加快药物筛查的策略以优化诊疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND/OBJECTIVES: Cannabis ingestions in young children frequently lead to emergency department (ED) visits requiring substantial diagnostic evaluation, including advanced neuroimaging. We assessed the relationship between presenting chief complaint, timing of cannabis test results, and the use of advanced neuroimaging in these visits.
METHODS: In this retrospective study using Epic's Cosmos database (January 2016 - June 2024), we included ED visits for children <6 years with a cannabis poisoning diagnosis and cannabis laboratory test. We described clinical characteristics and illustrated timing of drug testing results during these ED visits. We compared use of neuroimaging by chief complaint, using chi-squared tests and logistic regression.
RESULTS: There were 3653 encounters included. Median age was 29 (IQR 16-45) months and the cohort was 51 % female, 41 % White, 35 % Black, and 15 % Hispanic. The most common category of chief complaint was altered mental status (39 %), followed by ingestion/exposure (35 %), with seizures/abnormal movements present in 5 %. The median times from ED arrival to cannabis test collection and result were 93 (IQR 40-208) and 152 (IQR 90-277) minutes respectively. Neuroimaging was performed in 35 % of encounters, with significantly lower use in those with ingestion vs. neurologic chief complaints (8.8 % vs. 56 %; OR 0.08, 95 % CI: 0.06-0.10).
CONCLUSIONS: For children with cannabis poisoning, drug screen results were frequently unavailable until late in ED visits, and presenting chief complaint strongly influenced the use of neuroimaging. These findings underscore the need for strategies to facilitate early caregiver disclosure of ingestion and expedite drug screening to optimize care.
参考来源
- Walsh PS, Lipshaw MJ, Dupont AS, et al. Chief complaint, drug testing, and neuroimaging for cannabis poisoning in the emergency department. Am J Emerg Med. 2025. PMID: 40812254. doi:10.1016/j.ajem.2025.08.012
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。